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The purpose of this study was to evaluate in a double-blind placebo-based study
the effects of fiuoxetine over a period of 16 weeks on the frequency of binging
and purging and on fiuctuations in the levels of cariogenic organistns and saliva
secretion rate of patients (/; = 30) with bulima nervosa. Profile analysis suggested
that, over the course of the study, binging and purging frequency and Streptococ-
cus sobrinus salivary levels decreased significantly in the fiuoxetine group as cotn-
pared with the plaeebo group. Our finding that 5. sohrinus levels decreased 16
weeks after subjects were on medication suggests that the salivary levels of these
organistns could serve as an objectively measured indicator of patient compliance
with antibulimic therapy.
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Fiuoxetine is a specific blocker of sero-
tonin reuptake (12) that has been used
to decrease binge-eating and vomiting
in patients with bulimia nervosa (6-8,
1 1). We have previously reported (4)
that Streptococcus .sobrinus appears to
be an indicator of bulimic behavior (ac-
tive binging and purging). The purpose
of the present study was to evaluate in
a double-blind placebo-based study the
effects of fiuoxetine over a period of 16
weeks on the frequency of binging and
purging, on fiuctuations in the levels of
cat'iogenic organisms and on the rate of
saliva secretion of patients with bulimia
nervosa.
This investigation was perfortned on
a subset of subjects who participated
in a tnulticentet, double-blind, placebo-
controlled study of the efficacy and
safety of fiuoxetine. Approxitnately 400
patients at 15 different sites comprised
tlte trial study group. The multicenter
protocol included a 1-week, no-therapy
screenitig period and a 2-week, single-
blind placebo lead-in period. The study
subjects at the University of Michigan
site comprised 30 patients (29 women
and 1 man), 23 randomized to fiuoxet-
ine treatment and 7 to placebo treat-
ment. Patients frotn both groups were
well matched on age, age of onset of
bulitnic behavior, height and weight.
The patients received 60 mg orally each
day, over a course of 16 weeks. Cotnpli-
ance was assessed by pill counts per-
formed at each visit. Assessment of fre-
quency of binging and purging and of
oral microbial and salivary parameters
were performed at the end of the 2-
week, single-blind plaeebo period (base-
line); after 8 weeks on active drug or
placebo; and after 16 weeks on active
drug or placebo.
In order to be included in the study,
patients must have reported binge-eating
and votniting at least 3 times per week
for at least 6 months and had to meet all
DSM-III-R (3) criteria for bulitnia ner-
vosa. Symptoms must not have de-
creased markedly during the placebo
lead-in period. Binging and vomiting fre-
quencies were assessed by a patient diary
that was collected at each visit. We de-
veloped a scale in order to rate binge-
purge severity: 1: < than once a week; 2:
once a week; 3; twice a week; 4: 3 times a
week; 5:4 to 6 titnes a week; 6: > 7 titnes a
week. This scale was developed to refiect
changes in behavior that might be partic-
ularly relevant to changes in the oral fio-
ra of the patients.
Paraffin-stimulated whole saliva was
collected from subjects for 5 min from
which the saliva secretion rate was deter-
tnined (ml/min). The levels of eariogenie
organisms were assessed as previously
described (4). Briefiy, 1 tnl of saliva was
serially diluted at the ratios of 1:10, 1:100
and 1:1000 in reduced transport fiuid
and plated on selective media by tneans
of a spiral plating system. TYCSB me-
diutn for Streptococcus ntutans and S. so-
brinus (15), LBS agar for lactobacilli
(13), and Saboraud dextrose agar (SAB)
for yeasts were employed as selective me-
dia for these orgatiistns. The number of
colony-fonning units (CFU)/ml of sal-
iva was calculated after 2 to 3 days of an-
aetobic incubation (TYCSB and LBS)
and aerobic incubation (SAB), S. tmttans
and 5. sobrintts were distinguished by
colony tnorphology. Representative
colonies of these organisms from each
plate were submitted to a biochemical
scheme for the identification of the mut-
ans streptococci proposed by Shklair &
Keene (14). Organisms growing on the
TYCSB medium other than S. mutans
and S. ,sohrintts were found in M'Mi of the
plates (10 of 74).
The effects of lluoxetine or placebo
on microbial and salivary parameters
after 8 weeks and 16 weeks on medi-
cation were evaluated (Table I). None
of the microbial parameters differed sig-
nificantly between fiuoxetine and pla-
cebo groups. This may have been due
to patient attrition resultitig in a stnall
sample size or to the stnall size of the
placebo group as dictated by the study
designers. Another possible explanation
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•' Significantly different by rank paired /-test (/' = 0.04).
'' Signilieantly different by rank paired /-test from baseline to 8 weeks (/'<0.0001) and from baseline to 16 weeks (f = 0.057), in the lluoxetine
group.
is related to the reported frequency of
binging and purging. This study has
shown that subjects from both groups
were to a certain extent still binging and
purging at the end ol' the study" period,
which could contribute to the persist-
ence of aciduric organistns such as the
mutans streptococci, lactobacilli and
yeasts. The finding of no significant dif-
ferences between groups in tenns of the
levels of aciduric organisms may there-
fore refiect that the selection pressure
for aciduric organistns had not been
eliminated by fiuoxetine intake. The
salivary levels of S. .sobrintts, however,
significantly decreased at the 16-week
visit in the fiuoxetine group (Table I).
Wtthtn the fiuoxetine group, the sal-
iva secretion rate was significantly de-
creased after 8 weeks, a finding that
seetns to have persisted into the 16th
week of the study (Table 1). The fact
that the saliva secretion rate tneasured
objectively significantly decreased in the
subjects receiving fiuoxetine is an inter-
esting finding, as virtually no studies
have assessed the rate of saliva secretion
objectively before and after the use of
antidepressants. Parotid enlargement
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Fig. 1. Effeets of lluoxetine on salivary levels
of S. sobrinus, B: baseline. O: Huoxetine
group (;;= 15); mean + SE. •: placebo group
(/7 = 5); mean±SE.
among bulimics due to votniting (1, 10).
Certain conditions are associated with
parotid enlargement, such as work
hypertroplty and electrolyte imbalance,
which may result in decreased salivary
function. Indeed, correlations between
parotid enlargement and xerostomia
were observed in bulimics (2). Thus, the
objective measuiement of a decrease in
saliva secretion rate over the course of
this study in the treattnent group could
be a result of fiuoxetine usage, a result
of parotid dysfunction or a combination
of both.
The data from subjects who cotn-
pleted all phases of the study were ana-
lyzed by repeated-tneasures analysis of
variance (profile analysis). Fifteen sub-
jects in the fiuoxetine group and 5 sub-
jects in the placebo group had cotnplete
data. Profile analysis indicated that the
average category frequency of binging
(P = 0^0007) and purgitig (P = 0.0009)
decreased over the course of this study in
the fiuoxetine group cotnpared with the
placebo group, i.e., frotn an average of
at least daily binge-purge episodes to an
average of twice a week (data not
shown). These results are supported by
the combined results frotn all of the in-
vestigative sites of the lluoxetine multi-
center study (unpublished data), which
showed that, after 16 weeks, fiuoxetine
compared with placebo significantly re-
duced the average category frequency of
bingitig and purging (> 50% decrease in
vomiting or binge-eating episodes).
Profile analysis showed a decrease in
S. .sohrintts salivary levels (P = 0.016)
over the course of the study in the fiuox-
etine group compared with the placebo
group (Fig. I), regardless of the stnall
number of subjects in each group. A
possible explanation for the decrease of
S. .sobrimts in the fiuoxetine group is
that S. sohrinus is more dependent than
5". mtttans lor sucrose-mediated attach-
tnent to the tooth enamel pellicle (10).
Accordingly, a decrease in the frequency
of sugar itigestion (decrease iti the fre-
quency of binging) would tiot favor its
colonization. It was recently detnon-
strated that S. sobrinus is capable of
producing acid at low pH values,
whereas other mutans streptococci spe-
cies ceased acid productioti at sitnilar
pH values (5). Frotn these studies, we
may postulate that S. .sobrinus tnay be
highly active in acidic environments re-
fiecting current etnetic activity, as iti the
case of bulimic subjects, and that after
bulitnic episodes (purging) are reduced,
a decrease in the levels of 5. .sobrinus
may occur.
Our finding that S. .sobrimts salivary
levels were decreased 16 weeks after
subjects were on tnedication suggests
that the salivaty levels of these organ-
istns eould serve as an objectively tneas-
ured indicator of patient compliance
with antibulitnic therapy. This is in
agreetnent with our previous obser-
vation that, in untreated bulitnic indi-
viduals, tlte salivary levels of 5. .sobrinus
were elevated relative to a healthy
matched control group (4). The finding
that S. sobrinus could be used to moni-
tor bulimic behavior needs to be repro-
duced in larger population-based
studies. It would be of interest to eon-
duct future studies with the use of tnore
accurate assays for the enumeration of
S. .sobrinus such as monoclonal anti-
bodies and DNA probes.
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